BMO Capital Starts Aquestive Therapeutics (AQST) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
RBC Capital Starts Aquestive Therapeutics (AQST) at Outperform
August 20, 2018 8:07 AM EDTRBC Capital analyst Randall Stanicky initiates coverage on Aquestive Therapeutics (NASDAQ: AQST) with an Outperform rating and a price target of $23.00.
Stanicky said with stable cash flows from Suboxone behind it and a broad pipeline ahead of it, AQST is well... More
JMP Securities Starts Aquestive Therapeutics (AQST) at Market Outperform
August 20, 2018 5:06 AM EDTJMP Securities analyst Jason Butler initiates coverage on Aquestive Therapeutics (NASDAQ: AQST) with a Market Outperform rating and a price target of $29.00.
The analyst comments "The company's lead pipeline candidates address neurological diseases, where Aquestive is building commercial capabilities as it grows to... More
